- Home
- INTZ vs BCAB Comparison
INTZ vs BCAB Comparison
Compare INTZ & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTZ
- BCAB
- Stock Information
- Founded
- INTZ 1983
- BCAB 2007
- Country
- INTZ United States
- BCAB United States
- Employees
- INTZ N/A
- BCAB N/A
- Industry
- INTZ Computer Communications Equipment
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- INTZ Telecommunications
- BCAB Health Care
- Exchange
- INTZ Nasdaq
- BCAB Nasdaq
- Market Cap
- INTZ 33.2M
- BCAB 31.5M
- IPO Year
- INTZ 2020
- BCAB 2020
- Fundamental
- Price
- INTZ $1.69
- BCAB $0.72
- Analyst Decision
- INTZ Buy
- BCAB Hold
- Analyst Count
- INTZ 2
- BCAB 3
- Target Price
- INTZ $6.50
- BCAB $1.00
- AVG Volume (30 Days)
- INTZ 145.7K
- BCAB 1.1M
- Earning Date
- INTZ 10-08-2025
- BCAB 11-06-2025
- Dividend Yield
- INTZ N/A
- BCAB N/A
- EPS Growth
- INTZ N/A
- BCAB N/A
- EPS
- INTZ N/A
- BCAB N/A
- Revenue
- INTZ $6,828,000.00
- BCAB $11,000,000.00
- Revenue This Year
- INTZ $36.75
- BCAB N/A
- Revenue Next Year
- INTZ $30.90
- BCAB N/A
- P/E Ratio
- INTZ N/A
- BCAB N/A
- Revenue Growth
- INTZ 25.86
- BCAB N/A
- 52 Week Low
- INTZ $0.35
- BCAB $0.24
- 52 Week High
- INTZ $7.34
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- INTZ 50.68
- BCAB 56.79
- Support Level
- INTZ N/A
- BCAB N/A
- Resistance Level
- INTZ $1.74
- BCAB $0.84
- Average True Range (ATR)
- INTZ 0.08
- BCAB 0.07
- MACD
- INTZ -0.06
- BCAB -0.00
- Stochastic Oscillator
- INTZ 90.37
- BCAB 85.96
About INTZ Intrusion Inc.
Intrusion Inc is a cybersecurity company based in Plano, Texas. The group offers customers to access its threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol (IP) addresses. The company's product consists of On-Premise Network Protection, Cyber Threat Consulting, Cloud Network Security, and Endpoint Protection. Its solutions are INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. Its end-user customers include the U.S. federal government, state and local government entities, large and diversified conglomerates, and manufacturing entities.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.